A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis Clinical Trial

— GECKO  

Official title:

A Randomized, Double-blind, Placebo-controlled, Multicentre Phase 2 Study to Evaluate the Safety and Tolerability of Subcutaneous MOR106 Administered Concomitantly With Topical Corticosteroids for Eight Weeks, in Adult Subjects With Moderate to Severe Atopic Dermatitis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03864627
• Other study ID #: MOR106-CL-204
• Status: Terminated
• Phase: Phase 2
• Start date: March 25, 2019
• Est. completion date: February 27, 2020

Study information

• Verified date: December 2020
• Source: Galapagos NV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 33
• Est. completion date: February 27, 2020
• Est. primary completion date: February 27, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• A BMI 18 - 40 kilogram per meter square (kg/m^2), inclusive.
• Diagnosis of atopic dermatitis for at least one year since first diagnosis as per the Hanifin and Rajka Criteria.
• Eczema Area and Severity Index (EASI) = 16 at the screening and at the baseline visit (Day 1 predose).
• Investigators' Global Assessment (IGA) score = 3 (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe) at the screening and baseline visits.
• Greater than or equal to 10% body surface area (BSA) of AD involvement at the screening and baseline visits.
• Willingness to use a non-medicated, simple bland emollient twice daily for at least 7 days before the baseline visit and throughout the study.

Exclusion Criteria:

• Prior treatment with MOR106.
• Known hypersensitivity to any investigational medicinal product (IMP) ingredients as determined by the investigator (such as, but not limited to, anaphylaxis requiring hospitalization).
• AD lesions located predominantly (= 50% of cumulative lesional area) on face and genital areas.
• Any concurrent illness, condition, disability, or clinically significant abnormality (including laboratory tests, a New York Heart Association Classification (NYHA) = III/IV) or clinically significant illness in the 3 months prior to initial IMP administration that, in the investigator's opinion, represents a safety risk for the participant's participation in the study, may affect the interpretation of clinical safety or efficacy data, or may prevent the participant from safely completing the assessments required by the protocol.
• Clinically significant abnormalities at the discretion of the investigator detected on vital signs or physical examination (other than AD) at screening or baseline (Day 1 predose).
• History of or a current immunosuppressive condition (e.g. human immunodeficiency virus [HIV] infection, as determined by a positive HIV test at screening).
• Active chronic or acute skin infection requiring treatment with systemic (oral, sc or iv) antibiotics, antivirals or antifungals within 4 weeks of baseline, or clinical signs of infective eczema within 7 days before baseline (Day 1 pre-dose).
• Having used any of the following treatments:
• Prior exposure to Dupilumab.
• Immunosuppressive/immunomodulating drugs (e.g. systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon (IFN)-?, azathioprine, methotrexate) within 4 weeks of baseline (Day 1) visit.
• Phototherapy (ultraviolet B [UVB] or Psoralen Ultraviolet A [PUVA]) for AD within four weeks of baseline (Day 1) visit.
• Treatment with TCS or topical calcineurin inhibitor (TCI) within 7 days before the baseline (Day 1) visit.
• Treatment with biologics within five half-lives (if known) or 12 weeks prior to baseline visit, whichever is longer.
• Regular use (more than two visits per week) of a tanning booth/parlor within 4 weeks of the baseline visit.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• MOR106
MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
• Placebo
Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).

Locations

Country	Name	City	State
United States	First OC Dermatology	Fountain Valley	California
United States	Encore Medical Research	Hollywood	Florida
United States	Advanced Research Institute of Miami LLC	Homestead	Florida
United States	Center for Clinical Studies	Houston	Texas
United States	Marvel Research, LLC	Huntington Beach	California
United States	Dawes Fretzin Clinical Research Group, LLC	Indianapolis	Indiana
United States	LA Universal Research Center, Inc.	Los Angeles	California
United States	DS Research	Louisville	Kentucky
United States	Vista Health Research	Miami	Florida
United States	Greenwich Village Dermatology	New York	New York
United States	Arlington Dermatology	Rolling Meadows	Illinois
United States	Progressive Clinical Research	San Antonio	Texas
United States	MedDerm Associates	San Diego	California
United States	Center for Clinical Studies	Webster	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Galapagos NV

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Adverse Event of Special Interest (AESIs), Serious Adverse Events (SAEs)	An Adverse Events (AE) was any untoward medical occurrence, new or worsening of any pre-existing condition, in a clinical study participant administered a medicinal product and which did not necessarily had to have a causal relationship with the treatment. TEAEs: AES with an onset date on or after the start date of the IMP administration. AESIs: skin-related events (SRE) (except exacerbation and infective exacerbation of AD) or injection site reactions (ISRs) as per common terminology criteria for AEs (Grade 3: ulceration or necrosis; severe tissue damage; operative intervention indicated, Grade 4: life-threatening consequences; urgent intervention indicated, Grade 5: death ). An SAE: AE that resulted in any of the following outcomes: death; life threatening; results in persistent or significant disability/incapacity; requires in-patient hospitalization or prolongation of existing hospitalization; congenital anomaly/birth defect; is medically significant.	Day 1 up to Day 169/Early discontinuation(ED)
Secondary	Serum Concentrations of MOR106		Day 1, Day 4, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141, Day 155 and Day 169
Secondary	Number of Participants With Anti-drug Antibodies (ADAs)		Day 1 up to Day 169/ED